Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups

To quantify the magnitude of differences between observed overall survival and respective, age‐adjusted Social Security Administration life tables‐derived life expectancy in Caucasian, African American, Hispanic/Latino and Asian metastatic prostate cancer patients. Furthermore, to test for differences in cancer‐specific mortality and other‐cause mortality according to race/ethnicity.

[1]  K. Chi,et al.  Apalutamide for metastatic, castration‐sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double‐blind, placebo‐controlled phase 3 TITAN study , 2020, International journal of urology : official journal of the Japanese Urological Association.

[2]  Life expectancy at birth, by sex, 2000 and 2017 (or nearest year) , 2020, Health at a Glance: Latin America and the Caribbean 2020.

[3]  F. Saad,et al.  The Impact of Race and Age on Distribution of Metastases in Patients with Prostate Cancer. , 2020, The Journal of urology.

[4]  M. Terris,et al.  Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality. , 2019, JAMA oncology.

[5]  N. Agarwal,et al.  Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. , 2019, The New England journal of medicine.

[6]  Edmund Chiong,et al.  The incidence, mortality, and risk factors of prostate cancer in Asian men , 2018, Prostate international.

[7]  R. Cress,et al.  Changing Incidence of Metastatic Prostate Cancer by Race and Age, 1988-2015. , 2019, European urology focus.

[8]  F. Saad,et al.  Validation of the Social Security Administration Life Tables (2004-2014) in Localized Prostate Cancer Patients within the Surveillance, Epidemiology, and End Results database. , 2019, European urology focus.

[9]  D. Moreira,et al.  Prostate cancer disparities in Hispanics by country of origin: a nationwide population-based analysis , 2018, Prostate Cancer and Prostatic Diseases.

[10]  J. Brooks,et al.  Trends in incidence and 5‐year mortality in men with newly diagnosed, metastatic prostate cancer—A population‐based analysis of 2 national cohorts , 2018, Cancer.

[11]  S. Eggener,et al.  African-American Prostate Cancer Disparities , 2017, Current Urology Reports.

[12]  M. Carducci,et al.  Impact of ethnicity on the outcome of men with metastatic, hormone‐sensitive prostate cancer , 2017, Cancer.

[13]  T. Choueiri,et al.  Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  F. Saad,et al.  Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study , 2017, International Urology and Nephrology.

[15]  David F Jarrard,et al.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. , 2015, The New England journal of medicine.

[16]  K. Attwood,et al.  Androgen Receptor Mutations and Polymorphisms in African American Prostate Cancer , 2014, International journal of biological sciences.

[17]  R. deVere White,et al.  No improvement noted in overall or cause‐specific survival for men presenting with metastatic prostate cancer over a 20‐year period , 2014, Cancer.

[18]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[19]  Pierre I Karakiewicz,et al.  A population‐based competing‐risks analysis of the survival of patients treated with radical cystectomy for bladder cancer , 2011, Cancer.

[20]  Cancer Facts & Figures 2021 , 2010 .

[21]  B. Hollenbeck,et al.  Five‐year survival after surgical treatment for kidney cancer , 2007, Cancer.

[22]  T. Namiki,et al.  Comparison of the clinical outcome after hormonal therapy for prostate cancer between Japanese and Caucasian men , 2006, BJU international.

[23]  Å. Borg,et al.  CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk , 1999, British Journal of Cancer.